Impurities

At Manasa Life Sciences, we employ advanced analytical techniques to detect and quantify impurities in pharmaceutical substances. Our capabilities include Gas Chromatography (GC) and High-Performance Liquid Chromatography (HPLC) for precise separation and quantification, Ultraviolet (UV) and Infrared (IR) Spectroscopy for structural and functional group analysis, Nuclear Magnetic Resonance (NMR) Spectroscopy for detailed molecular characterization, and Mass Spectrometry (MS) for highly accurate mass determination. These state-of-the-art methods ensure reliable impurity profiling, regulatory compliance, and high-quality pharmaceutical products.

We implement comprehensive quality audits, continuous monitoring, and ICH Q3A-compliant processes to minimize impurities throughout the manufacturing process. This ensures the production of safe, effective, and high-quality pharmaceutical products for clients worldwide. We serve global markets with reliable delivery, complete traceability, and strict adherence to Good Documentation Practices (GDP) for impurity management.

Impurities are undesirable compounds that may remain in Active Pharmaceutical Ingredients (APIs). When present above acceptable limits, they can cause unintended pharmacological or toxicological effects, potentially compromising the safety, efficacy, and quality of the final pharmaceutical product. These impurities may originate from raw materials, chemical reagents, intermediates, atmospheric contamination, storage conditions, drug degradation, or microbial contamination. Effective impurity control is maintained throughout every stage of API manufacturing to ensure compliance with the highest quality and regulatory standards.

Types of Impurities

• Impurities in APIs are broadly classified into three categories:

• Organic Impurities

• Originate from starting materials, by-products, intermediates, or degradation products.

• Identified as volatile, non-volatile, or unknown compounds and analyzed for chemical structure and safety.

• Controlled according to ICH guidelines, with thorough evaluation during synthesis.

• Inorganic Impurities

• Arise from reagents, salts, heavy metals, or catalysts used in manufacturing.

• Quantified using pharmacopeial or validated methods, with strict adherence to safety limits.

• Residual Solvents

• Also called organic volatile contaminants, remaining from API, excipient, or finished product manufacturing.

• Classified as undesirable substances and controlled even at trace levels.

• Identified and quantified using Gas Chromatography (GC), following ICH Q3C guidelines.

• Control and Monitoring of Impurities

Organic impurities: Monitored through raw material evaluation, reaction intermediates, stress testing (ICH Q1A), and batch analysis during process development and commercial production.

Inorganic impurities: Assessed for catalyst carry-over and other contaminants using pharmacopeial methods, with acceptance criteria based on safety and regulatory standards.

Residual solvents: Controlled through validated manufacturing processes in compliance with ICH Q3C guidelines.

Manasa Life Sciences, located in India, we are a leading manufacturer of high-quality System Suitability Standards (SSS) for the pharmaceutical and API industries. We specialize in the manufacturing analytical reference standards in full compliance with cGMP, regulatory guidelines, and data integrity principles. Our standards are prepared using qualified API working standards and certified impurity reference materials under strict laboratory controls, utilizing calibrated instruments and validated analytical methods. Each batch undergoes severe evaluation for critical parameters such as resolution, tailing factor, theoretical plates, and precision, ensuring accurate and reliable system performance. Supported by good documentation practices and consistent quality assurance, we provide traceable, reliable, and high-quality System Suitability Standards to support HPLC, GC, and other chromatographic testing across the pharmaceutical and API sectors worldwide.

We also specialize in the manufacture of high-quality Peak Identification Standards, designed to support accurate impurity profiling, peak identification, and analytical method development. Our standards are prepared using qualified reference materials and thoroughly characterized using validated chromatographic techniques, including HPLC and GC, to ensure precise identification based on retention time (RT), relative retention time (RRT), and spectral data. Manufactured under stringent cGMP-compliant conditions and supported by Good Documentation Practices (GDP) and strict adherence to data integrity principles, our Peak Identification Standards provide exceptional reliability, traceability, and batch-to-batch consistency. We are committed to delivering dependable analytical reference solutions that meet the highest regulatory and quality requirements of the global pharmaceutical and API industries.